With an annual list price of $26.5K, Leqembi is set to become one of the most expensive drugs based on annual costs to be covered by Medicare Part B. Leqembi's label says it "should be initiated" in those with mild cognitive impairment or mild dementia stage of Alzheimer's. These are earlier stages of the disease.
https://seekingalpha.com/news/3986276-biogen-eisai-leqembi-medicare-single-highest-drug-spend
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.